EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Open Access · CC BY-NC 4.0

Long‐Term Efficacy and Safety of Canakinumab in Patients With Tumor Necrosis Factor Receptor–Associated Periodic Syndrome: Results From a Phase III Trial

Marco Gattorno iD, Laura Obici, Inmaculada Calvo Penadés, Tilmann Kallinich, Susanne Benseler, Elise Dekker, Jérémy Lévy, Fabrizio De Benedetti iD, Helen Lachmann

Arthritis & Rheumatology · 2024

DOI: 10.1002/art.42695 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift Arthritis & Rheumatology, 2024. Verfasst von Marco Gattorno und 8 weiteren Autor:innen. Beteiligte Einrichtung: IRCCS Giannina Gaslini Institute, Genoa, Italy. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Antibodies, Monoclonal, Humanized, Fever, Hereditary Autoinflammatory Diseases. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Novartis Pharma AG.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

We aimed at assessing efficacy, safety, and tolerability of canakinumab in patients with tumor necrosis factor receptor–associated periodic syndrome (TRAPS) during a 72‐week long‐term, open‐label extension of the CLUSTER study.

Methods

Patients received open‐label canakinumab 150 or 300 mg, either every 4 weeks (q4w) or every 8 weeks, with up‐titration permitted after on‐treatment flares (maximum dose: 300 mg q4w). Efficacy assessments included physician global assessment of disease activity, number of flares, and serum C‐reactive protein (CRP) and serum amyloid A protein (SAA) levels. Adverse events were also reported. Results are described for the overall population and according to the cumulative dose of canakinumab adjusted for body weight (94% of patients achieved no or minimal disease activity. Most patients had either no (69.8%) or one flare (24.5%), whereas at baseline, the median number of flares was 9.0 per year. Median CRP levels remained at

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, MonoclonalAntibodies, Monoclonal, HumanizedFeverHereditary Autoinflammatory DiseasesHumansTreatment OutcomeSerum Amyloid A Protein

Substanzen

canakinumabAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedSerum Amyloid A Protein

Autor:innen und Institutionen

  • IRCCS Giannina Gaslini Institute, Genoa, Italy.
  • IRCCS Policlinico San Matteo Foundation, Pavia, Italy.
  • La Fe University and Polytechnic Hospital, Valencia, Spain.
  • Charité Universitätsmedizin Berlin and Deutsches Rheumaforschungszentrum, Berlin, Germany.
  • Alberta Children's Hospital, University of Calgary, Alberta, Canada.
  • Novartis Pharma AG, Basel, Switzerland.

ORCID-Profile: Marco Gattorno, Fabrizio De Benedetti

Förderung

  • Novartis Pharma AG

Zitieren

APA

Gattorno, M., Obici, L., Penadés, I. C., Kallinich, T., Benseler, S., Dekker, E., Lévy, J., De Benedetti, F., & Lachmann, H. (2024). Long‐Term Efficacy and Safety of Canakinumab in Patients With Tumor Necrosis Factor Receptor–Associated Periodic Syndrome: Results From a Phase III Trial. Arthritis & Rheumatology. https://doi.org/10.1002/art.42695

Vancouver

Gattorno M, Obici L, Penadés IC, Kallinich T, Benseler S, Dekker E, et al. Long‐Term Efficacy and Safety of Canakinumab in Patients With Tumor Necrosis Factor Receptor–Associated Periodic Syndrome: Results From a Phase III Trial. Arthritis & Rheumatology. 2024. doi:10.1002/art.42695

BibTeX
@article{Gattorno2024,
  author = {Gattorno, Marco and Obici, Laura and Penadés, Inmaculada Calvo and Kallinich, Tilmann and Benseler, Susanne and Dekker, Elise and Lévy, Jérémy and De Benedetti, Fabrizio and Lachmann, Helen},
  title = {Long‐Term Efficacy and Safety of Canakinumab in Patients With Tumor Necrosis Factor Receptor–Associated Periodic Syndrome: Results From a Phase III Trial},
  journal = {Arthritis & Rheumatology},
  year = {2024},
  doi = {10.1002/art.42695}
}
Kostenlos starten →